1. Home
  2. PT vs BCDA Comparison

PT vs BCDA Comparison

Compare PT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PT
  • BCDA
  • Stock Information
  • Founded
  • PT 2012
  • BCDA N/A
  • Country
  • PT China
  • BCDA United States
  • Employees
  • PT N/A
  • BCDA N/A
  • Industry
  • PT Computer Software: Programming Data Processing
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PT Technology
  • BCDA Health Care
  • Exchange
  • PT Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • PT 14.7M
  • BCDA 13.7M
  • IPO Year
  • PT 2018
  • BCDA N/A
  • Fundamental
  • Price
  • PT $0.97
  • BCDA $1.43
  • Analyst Decision
  • PT
  • BCDA Strong Buy
  • Analyst Count
  • PT 0
  • BCDA 1
  • Target Price
  • PT N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • PT 62.5K
  • BCDA 78.7K
  • Earning Date
  • PT 09-19-2025
  • BCDA 11-12-2025
  • Dividend Yield
  • PT N/A
  • BCDA N/A
  • EPS Growth
  • PT N/A
  • BCDA N/A
  • EPS
  • PT N/A
  • BCDA N/A
  • Revenue
  • PT $4,961,892.00
  • BCDA N/A
  • Revenue This Year
  • PT N/A
  • BCDA N/A
  • Revenue Next Year
  • PT N/A
  • BCDA N/A
  • P/E Ratio
  • PT N/A
  • BCDA N/A
  • Revenue Growth
  • PT 9.20
  • BCDA N/A
  • 52 Week Low
  • PT $0.76
  • BCDA $1.00
  • 52 Week High
  • PT $1.38
  • BCDA $3.20
  • Technical
  • Relative Strength Index (RSI)
  • PT 50.10
  • BCDA 56.59
  • Support Level
  • PT $0.92
  • BCDA $1.27
  • Resistance Level
  • PT $1.03
  • BCDA $1.34
  • Average True Range (ATR)
  • PT 0.05
  • BCDA 0.06
  • MACD
  • PT -0.00
  • BCDA 0.03
  • Stochastic Oscillator
  • PT 45.45
  • BCDA 93.75

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: